Guidance
Change in vaccine vial monitor (VVM) assignment for GlaxoSmithKline Rotarix product
This information bulletin addresses the implications and required guidance associated with the upcoming scheduled shift in vaccine vial monitor (VVM) of the GlaxoSmithKline Biologicals SA (GSK) Rotavirus vaccine, Rotarix®, from VVM type 14 (VVM14) to VVM type 7 (VVM7). The information below is intended for WHO/UNICEF staff, as well as Expanded Program for Immunization (EPI) managers or other partner agencies which support immunization programmes.
Authors
Languages
- English
Publication year
2017
Publisher
WHO
Type
Guidance
Categories
- Programme management
Diseases
- Rotavirus
Organisations
- World Health Organisation (WHO)
Tags
- Policy and legislation
Topic references
EPI-CORE-ROTA